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1. Introduction
Dementia is a neurodegenerative disorder characterized by a progressive decline in multiple 
cognitive domains leading to deterioration of daily living activities, including social and pro-
fessional functioning. The aging population has been increasing gradually, and in 1990, 26 
countries with more than 2 million elderly citizens aged 65 years and older were identified. It 
is expected that by 2013 another 34 nations will be added in the list. On the other hand, cal-
culations made in 2000 about the number of elderly peoples (over 65 years old) in the world 
reached the 420 million (7%), and they estimated around 1 billion by 2030 (12%), mainly in 
developing countries [1].
Without doubt, the most common form of dementia in elderly people is Alzheimer disease 
(AD), but it can occur even in patients with 40 years of age.
AD is a progressive disorder of multifactorial origin, well defined clinically with a number of 
biomarkers also well documented. According to the World Alzheimer Report from 2015, AD 
will increase exponentially as population ages being one of the biggest problems of our soci-
ety in this century [2]. Currently, 46.8 million people live with dementia all over the world, 
and this number will be duplicated every 20 years. Today, the calculated incidence of demen-
tia is 9.9 million new patients, one new one every 3.2 s.
The Monzino 80+ population-based study made in 2015 found that one quarter of 80+-year-
old person had dementia even in advanced stages which increased prevalence in extreme 
ages such as: 15.7% in persons aged 70–84 years to 52 and 65.9% in peoples aged 95–99 and in 
beyond 100 years, accordingly [3].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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Another author reports that 24.3 million patients have dementia at the present moment, and 
the incidence is 4.6 new cases yearly. They said the number of patients will be duplicated 
every 20 years to more than 81 million (71%) by 2040 most of them in developing nations [4]. 
Other author highlighted that the number of patients living with dementia (PLWD) will be a 
triple by 2050 [5].
We also agree with Vito Moretti [6] who wrote about “Update on Dementia” that the whole 
society should be involved in the mental health promotion to reduce risk of dementia and in 
new priorities for research purposes to identify new approaches to this problem and eradicate 
stigma and discrimination.
The delivery of therapeutic agents specifically designed to enhance memory and cognition in 
AD patients is increasing gradually. The limited efficacy of the drugs currently available is 
well known, and the introduction of these medications has shed an entirely new light on the 
field. Therefore, we believe that this is the best time to look at the past to understand the pres-
ent and perhaps gain insight into the future [7].
2. Ancient times
Neurological injuries, such as traumatic hemiparesis and cervical dislocation with paraplegia, 
were described in the well-known Edwin Smith surgical papyrus. Similarly, recognizable in 
the Ebers papyrus is a description of migraine, but the history of dementia is probably as old 
as mankind, at least since lifespan reached the age of 60 years of age. After several searches 
of previous record in the medical literatures in order to summarize the opinions for dementia 
in ancient China, the earliest description of dementia in the Yellow emperor’s internal classic 
it is found in a book written 2000 years ago. The term of dementia was first delivered by Hua 
Tuo (AD 140–208) in the book, Hua Tou Shen Yi Mi Zhuan [8].
In the above-mentioned book, the author mentioned that the insufficiency of flowing energy 
(Qi) is one of the causes of dementia among other such as the stagnation of phlegm; and the 
stasis of the blood which confirm that dementia disorders were investigated by traditional 
Chinese medicine in ancient times [8].
An inscription from the tomb of the vizier Westphal, dated c. 2455 BCE, seems to describe 
stroke, and Herodotus describes epilepsy in Hellenistic Egypt [9].
In the past, everyone presenting an incapacity for reasoning properly including psychosis, 
 neurosyphilis, and other mental disorder was labelled as dementia. Elderly patients presenting 
similar clinical manifestations, were considered secondary to hardening of the brain arteries.
Dementia has been described to in medical texts since ancient times. One of the earliest known 
references to dementia is delivered to the 7th century BC Greek philosopher Pythagoras, who 
included in that concept “senium” peoples aged oldest than 63 years old (a period of mental 
and physical decay), and after age of 80th being where “the scene of mortal existence closes after a 
great length of time that very fortunately, few of the human species arrive at, where the mind is reduced 
to the imbecility of the first epoch of infancy” [10].
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The Greek statesman and poet Solon established that if a male people’s loss his capacity for 
judgment due to old age then terms of man’s will might be invalidated, this happened in 
550 BC and the Chinese authors considered the medical term of dementia related to “foolish 
old person” [11].
Two ancient Greeks Aristotle and Plato (Figures 1 and 2) wrote about mental decay in elderly 
persons and they considered that process as an inevitable one affecting all old peoples with-
out possibility of its prevention. They also said that these kinds of person were not suitable 
to carry out high responsibilities or any position because this disorder affects their judgment, 
imagination, reasoning and memory [12].
A more advanced statement about dementia was established by Cicero who defined it as a 
process not inevitable related with the aging that “affect only those old men who were weak-willed.” 
Cicero also said that dementia could not happen in those persons who remained mentally 
active and with the capacity to learn new things. Unfortunately, the Aristotle’s medical writing 
prevailed for several centuries above the most modern Cicero’s views on aging, and other phy-
sicians such as Galen and Celsus simply highlighted the Aristotle’s belief [13]. Nevertheless, 
other authors from Greece and Rome delivered other ideas more similar to our modern con-
cept of dementia including many cognitive and behavioral symptoms of dementia [14].
May et al. [15] delivered the results of electronic searches of Zhong Hua Yi Dian (“Encyclopaedia of 
Traditional Chinese Medicine”), a CD of 1000 premodern (before 1950) medical books, for single herbs, 
and other natural products used for dementia, memory disorders, and memory improvement.
They found 127 different books containing 731 citations about products for treatment of memory 
disorders. A total of 110 natural products for the management of memory problems were identi-
fied including yuan zhi (Polygala tenuifolia), fu shen (Poria cocos), and chang pu (Acorus spp.) All 
the above-mentioned products have been cited many times in the literature over the past 180 years.
Figure 1. Roman copy in marble of a Greek bronze bust of Aristotle by Lysippos, c. 330 BC. The alabaster mantle is 
modern. Born 384 BC in Northen Greece. Died 322 BC in Euboea Greece (Source: https://en.wikipedia.org/wiki/Aristotle).
Introductory Chapter: Cognitive Disorders and Its Historical Background
http://dx.doi.org/10.5772/intechopen.77084
3
Dementia was defined in the ancient period (under Ayurveda) as well. The ancient period 
dates back to the mid-second millennium Before Christ (B.C.) during the creation of the 
Ayurvedic Indian system of Medicine, which detailed descriptions of neurological disorders 
called Vata Vyadhi. Knowledge about dementia was increasing gradually through the early 
twentieth century witnessed the birth of modern Indian medicine with the onset of formal 
physician training at the nation’s first allopathic medical colleges located in Madras (1835), 
Calcutta (1835) and Mumbai (1848) [16].
Neurology, in the modern sense, did not exist in ancient times, where medicine was a group 
of belief, magical, natural, and religious elements. There were different practitioners for each 
form of therapy. However, Egyptian doctors made careful observations of illness and injuries, 
including problems of the nervous system. Egyptians had words for the skull, brain, verte-
brae, spinal fluid and meninges, though they do not say if they assigned any function to them. 
They also described unconsciousness, quadriparesis, hemiparesis and dementia [17].
Even in contemporary societies, extended life expectancy results in elderly leaders, suffering 
from various diseases connected with gerontology and without exception, their peoples and 
the whole nation suffer the consequence. From 87 Byzantine emperors, 7 of them reached older 
age and showed symptoms of dementia, as well as other manifestations of elderly peoples.
Many Byzantine doctors considered dementia secondary to multiple causes mainly some 
kind of pathogenic humor and cerebro-vascular disorder.
Loss of mental skills is considered dangerous and remains a problem from antiquity to the 
modern day. Fortunately, Byzantium handled all these cases with diplomacy [18].
The reference to “imbecility” was described for the first time in Greece around sixth century 
BC and the Japanese term “Mow-roku” (age and devitalized) in eleventh century. In 1960, this 
Figure 2. Plato: Roman copy of a portrait bust by Silanion for the Academia Athens. Born 428/427 or 424/423 BC in 
Athens, Greece. Died 348/347 BC (age) c. 80. Athens (source: https://en.wikipedia.org/wiki/Plato).
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term was replaced by “Chee-hou” (absent-mind imbecile), and finally in 2014, it was changed 
by “Nonchee-show” for humanistic reasons [19].
In Constantinople, there was one special hospital to admit those patients with dementia or 
insanity excepting the emperors who were above the law and whose health problems could 
not be divulgated publicly. During 1700 years, information about dementia on Western medi-
cal literature was poorly recorded.
In the thirteenth-century, Roger Bacon wrote about dementia who considered advanced ages 
as celestial punishment for original sin. He also delivered the same Aristotelian’s criteria say-
ing that dementia is a natural consequence of long lifespan but established that the brain was 
the center of memory and not the heart [20]. Years later, poets, novelists, and other playwrit-
er’s mentioned the loss of mental function secondary to old age, and it should be highlighted 
Shakespeare and his allusion to dementia in his play Hamlet and King Lear [21, 22].
At that time, elderly people presenting dementia was called as senile dementia or senility, and 
it was considered as a normal consequence of the advance age and not a brain disorder, but 
years later, the same cause of the same problem was identified as cerebral atherosclerosis and 
or ischemic stroke in the cerebral vascular territory.
Before the end of nineteenth century, the concept of dementia is wider than twentieth century 
and later and under the umbrella of that definition, it was included several mental disorders 
and any type of psychosocial disability, including conditions that could be reversed [23].
The history of vascular dementia is related to patients presenting cognitive decline post apo-
plexy reported by Thomas Willis in 1672. In almost all eighteenth and at the beginning of 
nineteenth century, the pathological process of “brain congestion” was the most common 
diagnosis performed by the medical doctors when several conditions ranging from stroke to 
anxiety and to dementia due to effects of untreated hypertension were diagnosed.
The modern history of vascular dementia is written by Otto Binswanger and Allois Alzheimer 
(Figure 3). In 1894, they had a merit to distinguish vascular dementia from dementia para-
lytica caused by tertiary syphilis [24].
In 1907, a 50-year-old lady presenting a cognitive decline and some associate microscopy 
abnormalities in the brain was reported by Allois Alzheimer who considered it as a rare disor-
der of the middle age. Alzheimer’s findings were originally published in the form of a confer-
ence abstract where the author described a delusional woman (Auguste D) who had slowly 
lost her cognitive function and died at 55 years of age [25].
In recognition of the job done by Allois Alzheimer (1864–1915), Emil Kraepelin introduced 
the term of Alzheimer’s disease in 1910 and also differentiated the presenile form of dementia 
(reported by Alzheimer) from the commonest senile variant [26].
During the first half of the twentieth century, the vascular etiology for almost all cognitive dis-
orders was prevalent until 1960s where the link between neurodegenerative diseases and age-
related cognitive decline was documented. Ten years later, the vascular etiology of dementia 
is considered less common than was before though and AD the commonest cause of almost 
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all mental impairment in elderly peoples. Currently, it is well known that vascular dementia 
and AD can be associated.
Around 2010, many countries have 10–14% of people over 65 and in Germany and Japan, 
this percentage was even higher (>20%). As we mentioned earlier, life spasm over 80 years 
before twentieth century was extremely uncommon. Therefore, all disease related advanced 
age were rare as well.
Before World War II, elderly persons constituted an average of 3–5% of the population. 
Syphilitic dementia widespread all over the word until it was almost complete eradicated 
(when penicillin is discovered) after the war. We know that it allows increasing the life span 
expectancy in developed countries remarkably. Between 1913 and 1920, the medical term 
dementia praecox had been used to suggest the development of senile-type dementia at a 
younger age and this terminology also referred to patients with schizophrenia (including 
paranoia and decreased cognitive capacity) which could be expected to affect any elderly 
person [27].
In 1920, the uses of dementia for what is now understood as schizophrenia and senile demen-
tia helped limit the word’s meaning to “permanent, irreversible mental deterioration.” This 
began the change to the more recognizable use of the term today.
Prior to India’s independence from Britain in 1947, only 25 medical schools existed in the 
entire country where concepts about dementia were taught. In 1951, physicians across the 
field of neurology and neurosurgery united to create the Neurological Society of India (NSI). 
Figure 3. Emil Kraepelin in his later years. Born in 1856 and died in 1976 (aged 70). (Source: https://en.wikipedia.org/
wiki/Emil_Kraepelin).
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Four decades later in 1991, neurologists branched out to establish a separate organization 
called the Indian Academy of Neurology (IAN) where a lot of research on dementia was done. 
With the transition to modern medicine that occurred more recently through formal train-
ing at medical schools beginning in the 1930s, some criteria about different presentations on 
dementia changed. The future of neurology in India continues growing rapidly and currently, 
there are 1100 practicing neurologists attending patients with cognitive decline and dementia 
and more than 150 post-graduate trainees who join the ranks every year [16].
In 1970s, dementia was delineated from normal aging, and the present concept of dementia 
was established in Japan [19].
In 1970s, the concept of vascular dementia (VaD) is finally separated and internationally 
accepted from the purely neurodegenerative form of AD. Many efforts have been released 
in order to distinguish these entities from the clinical, neuropsychological and pathologi-
cal point of view for find out a homogenous group of patients who share a common spe-
cific underlying mechanism of cognitive decline [28]. The link between senile dementia and 
Alzheimer’s disease was published by Katzmann in 1976 [29]. He described the prevalence 
and malignancy of AD as a major killer in peoples older than 65 years based on identical 
pathological findings in both processes. He established non-pathological difference between 
senile dementia (older than 65) and AD occurring before 65 years old, and the treatment for 
both entities should be the same. He also considered “senile dementia” as part of aging and 
not a proper disease. Katzmann documented that AD is a common disease and the fourth or 
fifth leading cause of death. Thanks to Katzman’s criteria, dementia was not considered a part 
of the normal healthy aging process anymore but the debate between “senile dementia of the 
Alzheimer’s type (over 65 years old) and Alzheimer’s disease in younger peoples with the 
same pathology continue. It was agreed that the age limit was not certain, and the term AD 
should be reserved for those patients presenting the classical clinical manifestation and the 
brain pathology described regardless of the age of the patient.
Based on the evidence that many supercentenarians (more than 110 years old) have not 
dementia, these authors concluded that there was no age at which all persons develop AD, 
although the incidence of AD increases with age. Nevertheless, dementia is more frequent at 
the ages of 80 and 84 but peoples reaching the oldest stages have lower chance of developing 
it and women are more affected than men probably because women have longer lifespan than 
men [24].
Finally, psychiatry conditions like schizophrenia were removed from the organic brain syn-
drome group in 1952 and it was not considered as a cause of dementia anymore. On the other 
hand, the rational cause of senile dementia such as: hardening of the arteries became a main 
etiology for vascular dementias (VD) when presenting small strokes and now it is named: 
multi-infarct dementia.
In the 1960s, the seminal neuropathological and clinical studies of the New Castle school in 
England inaugurated the modern era of vascular dementia [24]. The general concern about 
AD increased gradually after 1994 when the US president Ronald Reagan disclosure he had 
been diagnosed with AD.
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The term dementia with Lewis Body and the clinical criteria were first introduced and pro-
posed by Mc Keith and colleagues in 1996 during the First International Workshop of the 
Consortium on Dementia with Lewy Bodies [30].
In the twenty-first century, many types of dementia have been identified being AD and VaD, 
the commonest one. Fortunately, from the last century, cognitive disorders such as idiopathic 
normal pressure hydrocephalus have specific treatment, and patients can reach a complete 
recovery.
Currently, apart for the advance role on the therapeutic field in almost all types of dementias, 
we highlighted the tremendous progress got in the field of diagnosis mainly in the field of 
pathological examination and metabolic activity in nuclear medical imaging tests such as 
single photon emission computed tomography and Positron Emission Tomography scans of 
the brain.
3. Brief comment about our chapters
In the second chapter of this project, we delivered our personal experience on the most common cogni-
tive disorders and discuss the novel information available in the medical literature on some types of 
dementia. We described Alzheimer Disease as a progressive non-reversible neurodegenerative disorder, 
characterized by cognitive decline including learning capacity, emotional and behavioral alterations, 
motor skills impairment, including dysfunction of the autonomic nervous system and desynchroniza-
tion of circadian rhythms. It has been predicted that a novel therapeutic agent that delays dis-
ease onset and progression by just 1 year would result in 9 million fewer cases by 2050 [31].
Vascular dementia (VaD) can be caused by disturbance of the blood supply to the brain lead-
ing to deprivation of the necessary such as nutrients including glucose, amino acids and 
oxygen to the neurons and its supporting cells. This particular type of dementia is strongly 
related with multifocal strokes, hypertension and diabetes mellitus type II and it is character-
ized by mental slowness; impaired initiative, planning, and executive function impairment; 
personality changes; and gait disorders. Arteriosclerotic brain disease presents as multiple 
focal areas of hypoperfusion randomly distributed in the cortex, also compromising sub-
cortical structures. This particular pattern is never been observed in A.D. A familial form 
of VaD is cerebral autosomal dominant arteriopathy with subcortical infarcts and leuko-
encephalopathy (CADASIL), which is associated with vascular migraine headache and a 
subcortical ischemic lesion. CADASIL is caused by a mutation in the NOTCH3 gene on chro-
mosome 19 being the most common genetic form of VaD. The disease is autosomal dominant. 
Dementia with Lewis Body is a type of dementia associated with abnormal protein deposits 
(α-synuclein) called Lewy bodies in the central nervous system (CNS), and these abnormal 
depositions affect the normal activities of the brain leading to clinical features of fluctuating 
consciousness, behavioral disorders, visual hallucinations, and parkinsonism. The metabolic 
defects described in this disease are very close to those found in AD, but there is also hypo-
perfusion in the occipital lobes. Parkinson dementia is characterized by bradykinesia, tremor 
at rest, gait disturbance, postural problems, rigidity, dysarthria, dysfunction of the judgment, 
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reasoning, memory, depression, anxiety, insomnia, and cognitive decline due to loss of mid-
brain dopaminergic neurons in the pars compacta of the substantia nigra and consequent loss 
of dopamine input to the caudate nucleus and putamen (striatum), and is more prevalent in 
men. Idiopathic Parkinson disease with dementia can show hypoperfusion patterns similar 
to those observed in AD, but basal ganglia hypoperfusion is far more frequent, as is frontal 
precentral hypoperfusion [32].
Dementia is also part of the clinical manifestation of some types of Parkinsonism such cortico-
basal degeneration in which bilateral and symmetrical hypoperfusion of the frontal, parietal 
lobe and basal ganglia are present. There is symmetrical severe basal ganglia hypoperfusion 
also affecting the mesial regions of the frontal lobes in supranuclear palsy. The hallmark find-
ing in multiple system atrophy is cerebellar hypoperfusion, besides symmetric basal ganglia 
hypoperfusion [33].
Mixed Dementia: the association of AD and vascular dementia is the commonest cause of 
mixed dementia. Idiopathic normal pressure hydrocephalus is characterized by late onset, 
surgically treated progressive neurodegenerative disease caused by inadequate cerebrospinal 
fluid (CSF) dynamics and ventriculomegaly while other types including low pressure hydro-
cephalus are usually secondary to head injury, subarachnoid hemorrhage, infections, and 
other problems that cause an accumulation of the cerebrospinal fluids (CSF) in the ventricular 
system of the brain mainly associated to its impaired drainage. Wernicke encephalopathy 
and Korsakoff syndrome (Wernicke-Korsakoff syndrome) and Alcohol related dementia are 
preventable, life-threatening neuropsychiatric syndromes resulting from thiamine deficiency 
mainly in patients with chronic alcoholism, anorexia nervosa or patients that have undergone 
bariatric surgery for obesity, chronic hepatic disease, immunodeficiency syndromes, nutri-
tional deficiencies of any cause, metastatic carcinomas, hyperthyroidism, prolonged paren-
teral nutrition, hyperemesis gravidarum, long-term dialysis and diuretic therapy among other 
causes and clinically, patients’ complaints about short-term memory, confusional states, and 
neuropsychiatry manifestations, HIV-associated neurocognitive disorders (HAND). Many of 
the complications secondary to HIV-1 infection (including all opportunistic infections) have 
decreased dramatically excepting HAND which is quite common CNS disorder caused by HIV 
infection. Huntington disease: in our series of patients presenting Huntington’s disease (HD), 
an important number of them do not have extrapyramidal signs of chorea. Frontotemporal 
dementia: patients with the different diseases in this group present severe bilateral hypoper-
fusion in the frontal lobes, predominantly in the mesial structures [34].
We comment about Creutzfeldt Jacob Disease as an extremely uncommon degenerative dis-
order due to a slow virus (prion) infection that affects the brain and it is also known as mad 
cow disease. The diagnosis of CJD is usually made when patient older than 60-year-old died 
and the spongiform changes in the brain post-mortem examination are confirmed. We also 
discussed about the available update information on the commonest cognitive screening test 
used to evaluate cognition, and finally we documented our conclusion from previous inves-
tigations done.
In the chapter titled “Identification of cognitive impairment markers (Neurospecific proteins, 
Magnetic Resonance Image) in patients with Diabetes Mellitus type 1,” the authors studied 
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the effects of metabolic disorders on the development of cognitive disorders in patients pre-
senting the abovementioned disorder. They concluded that chronic hyperglycemia and glu-
cose variability are risk factors for the development of cognitive dysfunction, which confirm 
the need for more severe compensation of the disease. They also highlighted: “For type 1 
diabetic patients with unsatisfactory compensation of carbohydrate metabolism the neuro-
physiological tests looking for cognitive decline should be done.”
In the chapter: Dementia Friendly Assistive Brotherhood Communities, authors from 
Bournemouth University in United Kingdom highlighted the usability of an assistive soft-
ware application developed for 8 patients living with dementia (PWLD) and 40 volunteers at 
5 different cities of Pakistan.
Overall, the PWLD showed great interest in all the functionalities of the assistive brother-
hood community application and were keen to adopt it permanently in their daily life activi-
ties. The PWLD specifically appreciated the increased socialization opportunities through the 
use of assistive brotherhood community application. The implementation of assistive broth-
erhood community application in the lives of the PWD will increase their confidence, self-
esteem, and independence.
Another important chapter on Re-framing and Re-thinking Dementia in the Correctional 
Setting is written by two authors from University of Adelaide and University of South 
Australia. They raise the concern about the aging population in the Australian correctional 
setting. They highlighted the increasingly complex healthcare needs in the prisoner popula-
tion who present with poorer physical, social, and mental health than the general population, 
and they also concluded that healthcare services within the correctional environment needs to 
match that in the general community and this requires the development of policies to support 
staff to put processes in place that will improve health outcomes for prisoners.
One chapter written by two Korean colleagues from Korea Institute of Science and Technology 
cover the most relevant aspects of Tau in Tauopathies that leads to Cognitive Disorders and 
in Cancer. They refer Tau as a copious microtubule-associated protein mainly expressed in 
neurons; it is also expressed in non-neuronal cell. Tauopathies are neurodegenerative diseases 
occurring mostly within the neuronal and glial cells of the central nervous system with a con-
spicuous tau pathology. Tau might have significant functions in non-neuronal cells. In this 
chapter, authors describe the associations between tauopathies and cancer.
Nowadays, some drugs used for the treatment of cancer are also used for the treatment of 
different neurological disorders like Parkinson’s disease and AD. They said that Nilotinib is 
an FDA-approved protein tyrosine kinase inhibitor (TKI)—used for the treatment of chronic 
myeloid leukemia but it also targets AD and produces neuroinflammation and misfolded 
proteins that ultimately reduce cognitive damage. In Parkinson’s disease, nilotinib triggers 
autophagy to remove hyperphosphorylated tau from the brain before they accumulate as 
plaques.
The hypothalamus plays a central role in autonomic functions, including the generation and 
control of the circadian rhythms, the thermoregulation, the homeostasis of proteins, the main-
tenance of energy supply and the feeding behavior. Five authors from Aristotelian University, 
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Department of Neurology, Laboratory of Neuropathology and Electron Microscopy in Greece 
afforded this topic (The hypothalamus) and the AD and made a Golgi and electron micro-
scopic study.
They found that the pathological alterations of hypothalamic nuclei in AD would induce the 
autonomic instability, which would be particularly prominent at the advanced stages of the 
disease, aggravating the clinical condition of the patients exceedingly, a fact which is also 
observed in experimental models of AD as well as in the behavioral variant of frontotemporal 
dementia.
Finally, they concluded that a serious autonomic dysfunction in advanced stages of AD com-
pose the tragic epilogue of the disorder which is related with the involvement of the hypo-
thalamus during the continuous pathological process of the disease.
Other authors from New Zealand made a study about “Effective Restoration Home Support 
for Older Peoples Living with Dementia and their Caregivers.” One of the most relevant 
aspects of this investigation was the identification of 10 key factors supporting the adequate 
restorative home support services for those patients. Its grouped in three primary headings 
that are congruent with the information published in the medical literature, and they have 
international implications which include policy and practice that keep the needs and well-
being of the dementia diagnosed person and their caregiver central to all decision-making and 
keeping track of their progression. They also agreed that local solution will influence future 
decision-making, and this is one of the most important aspects that this chapter highlighted.
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